- Lobbying
- cigna AND corporation
Lobbying Arrangements Results for 'Cigna Corporation'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Monitor issues related to drug pricing |
Cigna Corporation
Health Care Services |
LEVINE & COMPANY | |||
Details Issues related to competition |
The Cigna Group and subsidiaries (Formerly Cigna Corporation and subsidiaries)
|
WILMER CUTLER PICKERING HALE AND DORR LLP | |||
Details Issues related to health care policy |
Cigna Corporation
|
Bose Public Affairs Group | |||
Details Monitored issues related to Pharmacy Benefit Manager (PBM) and broader insurance market regulation. |
Cigna Corporation
|
Wynne Health Group | |||
Details Pharmacy issues related to TRICARE and the FY 2024 National Defense Authorization Act and the FY 2024 Department of Defense Appropriations legislation. S. 127 - Pharmacy Benefit Manager Transparenc... |
The Cigna Group and subsidiaries (FKA Cigna Corporation and subsidiaries)
|
Banner Public Affairs, LLC | |||
Details Issues relating to health care policy. |
Cigna Corporation
|
Eris Group (formerly known as Bartlett & Bendall) | |||
Details Proposals impacting Medicare Advantage and Medicare Part D; Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy and prescription drug pricing policy; H.R.5378 - Lower Cost, Mor... |
Cigna Corporation and subsidiaries
|
Tiber Creek Group | |||
Details Issues related to Medicare, Health Savings Accounts, Small Business Health Plans and Health IT |
Cigna Corporation
Employee benefits company |
Blank Rome Government Relations LLC | |||
Details Monitor issues regarding pharmaceutical benefit managers. Issues relating to drug pricing. Issues relating to trade agreements. |
Cigna Corporation
|
The Gibson Group, LLC | |||
Details Foster care issues |
Casey Family Programs
National child welfare organization |
Heather Podesta + Partners, LLC | |||
Details Provide advice and counsel on healthcare coverage, surprise billing, drug pricing and Affordable Care Act issues; Drug pricing and issues facing the pharmacy benefit manager industry generally |
Cigna Corporation
|
POLARIS GOVERNMENT RELATIONS, LLC | |||
Details Issues relating to regulatory reform legislation Affordable Health Choices Act Congressional Oversight of the Health Care Industry |
CIGNA Corporation
|
STEPTOE & JOHNSON LLP | |||
Details Issues related to Trump Administration proposals and regulations regarding drug pricing reforms, regulations regarding rebates, and related guidances focused on affordability and accessibility to p... |
Cigna Corporation
Health Care Services |
Nathanson+Hauck | |||
Details Issues related to the Improving Seniors Timely Access to Care Act of 2021; Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Techni... |
The Cigna Group and subsidiaries (Formerly Cigna Corporation and subsidiaries)
|
in-house lobbying | |||
Details Tax treatment of financial services income under international tax reform proposals. |
Financial Services International Tax Reform Working Group (Ad Hoc Coalition)
|
Ernst & Young LLP (Washington Council Ernst & Young) | |||
Details -Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 20... |
The Dual Eligible Coalition
|
Leavitt Partners, LLC | |||
Details Proposals that impact Medicare Part D. Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. Issues related to H.R. 7839 Continuing Access to In Home IVIG Act.... |
Cigna Corporation
|
Tiber Creek | |||
Details Monitored the implementation of H.R. 5376 (P.L. 117-169), the Inflation Reduction Act, as it relates to health care. Monitored issues related to mental health. Monitored issues related to insulin. ... |
CIGNA Corporation
|
THE NICKLES GROUP, LLC | |||
Details Educate policymakers on pharmacy issues related to TRICARE and H.R. 2670, S.2226 Fiscal Year 2024 National Defense Authorization Act; issues related to removing barriers to biosimilar medicine acce... |
CIGNA Corporation
|
Invariant LLC |